Indication

Postmenopausal urethral atrophy

Postmenopausal urethral atrophy is a lower urinary tract manifestation of genitourinary syndrome of menopause (GSM), caused by declining circulating estrogen levels following menopause. Read more about Postmenopausal urethral atrophy

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Postmenopausal urethral atrophy therapies.

Showing 1–2 of 2 drugs

Filter & compare in the drug finder →Opens the drug finder with Postmenopausal urethral atrophy preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Postmenopausal urethral atrophy.

Postmenopausal urethral atrophy is a lower urinary tract manifestation of genitourinary syndrome of menopause (GSM), caused by declining circulating estrogen levels following menopause.

Due to shared embryologic origins with the vaginal epithelium, the female urethra is rich in estrogen receptors; estrogen deficiency leads to cellular thinning of the mucosal lining, loss of vascularity, reduced collagen elasticity, and impairment of the urethral mucosal seal.

Clinically, affected postmenopausal women present with irritative urinary symptoms, including dysuria, frequency, urgency, urge or stress urinary incontinence, and an increased susceptibility to recurrent urinary tract infections.

Personalize your experience

Follow Postmenopausal urethral atrophy and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it